Your browser doesn't support javascript.
loading
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Haag, Georg Martin; Springfeld, Christoph; Grün, Barbara; Apostolidis, Leonidas; Zschäbitz, Stefanie; Dietrich, Mareike; Berger, Anne-Katrin; Weber, Tim Frederik; Zoernig, Inka; Schaaf, Marina; Waberer, Lisa; Müller, Daniel Wilhelm; Al-Batran, Salah-Eddin; Halama, Niels; Jaeger, Dirk.
Afiliação
  • Haag GM; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Applied Tumor-Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: GeorgMartin.Haag@med.uni-heidelberg.de.
  • Springfeld C; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Grün B; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Apostolidis L; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Zschäbitz S; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Dietrich M; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Berger AK; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Weber TF; Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Zoernig I; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Schaaf M; IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, Germany.
  • Waberer L; IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, Germany.
  • Müller DW; University Cancer Center Frankfurt, Institut für Klinisch-Onkologische Forschung and IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, Germany.
  • Al-Batran SE; University Cancer Center Frankfurt, Institut für Klinisch-Onkologische Forschung and IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, Germany.
  • Halama N; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jaeger D; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Applied Tumor-Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Eur J Cancer ; 167: 112-122, 2022 05.
Article em En | MEDLINE | ID: mdl-35427833
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Reparo de Erro de Pareamento de DNA Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Reparo de Erro de Pareamento de DNA Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2022 Tipo de documento: Article